Dermira (NASDAQ: DERM) reported Q1 EPS of ($1.49), $0.13 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $2.64 million.

“Positive momentum continued into the first quarter 2019 at Dermira. Bolstered by significant prescription growth of QBREXZA and the positive topline efficacy and safety results from our lebrikizumab Phase 2b study in atopic dermatitis, we’ve never been in a stronger position,” said Tom Wiggans, chairman and chief executive officer of Dermira. “As we look ahead to the rest of the year, we are focused on continuing our efforts to build awareness of QBREXZA to drive prescription demand and sales growth, initiating the Phase 3 clinical development program for lebrikizumab following discussions with the U.S. Food and Drug Administration, exploring lifecycle opportunities for our existing programs, and maintaining a strong balance sheet. These efforts will allow us to continue delivering on our commitment to bring innovative, new therapies to patients with chronic skin conditions.”

For earnings history and earnings-related data on Dermira (DERM) click here.